Villatoro Antonio J, Claros Silvia, Fernández Viviana, Alcoholado Cristina, Fariñas Fernando, Moreno Antonio, Becerra José, Andrades José A
ImmuneStem, Instituto de Inmunología Clínica y Terapia Celular, 29018, Málaga, Spain.
Laboratory of Bioengineering and Tissue Regeneration (LABRET), Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, Biomedicine Research Institute of Malaga (IBIMA), Campus Universitario de Teatinos, 29071, Málaga, Spain.
BMC Vet Res. 2018 Mar 27;14(1):116. doi: 10.1186/s12917-018-1413-4.
Feline eosinophilic keratitis (FEK) is a chronic keratopathy caused by a suspected immune mediated response to an unknown antigenic stimulus. The purpose of this study was to investigate the safety and therapeutic effects of allogeneic feline adipose-derived mesenchymal stromal cells (fAd-MSCs) implanted subconjunctival around the ocular surface lesion in five cats with FEK refractory to current available treatments.
FEK was diagnosed by clinical appearance and evidence of eosinophil and/or mast cells in corneal cytology. Each animal was treated with two applications of 2 × 10 million of fAd-MSCs 2 months apart. Ocular surface integrity was assessed before treatment and at 1, 3, 6 and 11 months after treatment. Clinical signs showed a significant change during the follow-up with resolution of the corneal and conjunctiva lesions and there were no signs of regression or worsening.
Implanted cells were well-tolerated and effective reducing clinical signs of FEK with a sustained effect during the study period. None of the animals showed systemic or local complications during the study. To our knowledge, this is the first time in literature that local implantation of allogeneic fAd-MSCs has been found as an effective therapeutic alternative to treat cats with FEK.
猫嗜酸性粒细胞性角膜炎（FEK）是一种慢性角膜病，由对未知抗原刺激的疑似免疫介导反应引起。本研究的目的是调查同种异体猫脂肪来源间充质基质细胞（fAd-MSCs）结膜下植入眼表病变周围对五只现有治疗方法难治的FEK猫的安全性和治疗效果。
通过临床表现以及角膜细胞学中嗜酸性粒细胞和/或肥大细胞的证据诊断FEK。每只动物在两个月的间隔内接受两次2×1000万个fAd-MSCs的应用。在治疗前以及治疗后1、3、6和11个月评估眼表完整性。临床体征在随访期间有显著变化，角膜和结膜病变消退，没有复发或恶化的迹象。
植入的细胞耐受性良好，有效减轻了FEK的临床体征，在研究期间具有持续效果。在研究过程中，没有动物出现全身或局部并发症。据我们所知，这是文献中首次发现局部植入同种异体fAd-MSCs是治疗FEK猫的有效治疗选择。
